micro-community-banner
Profile Image
  • Saved
Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1

Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1

Source : https://pubmed.ncbi.nlm.nih.gov/38710625/

Familial hypobetalipoproteinemia (FHBL) 1 is a rare genetic disorder with an autosomal codominant mode of inheritance and is caused by defects in the apolipoprotein (apo) B (APOB) gene that disable...

Although homozygous or compound heterozygotes of familial type 1 hypobetalipoproteinemia (HoFHBL1) and abetalipoproteinemia cannot be distinguished from the clinical manifestations and laboratory findings of the proband, moderate hypolipidemia in first-degree relatives may help diagnose HoFHBL1.

Profile Image
  • Saved
Metabolic Dysregulation and Its Multifaceted Impact on Cardiovascular Autonomic Control in Type 2 Diabetes Mellitus: Insights From Comprehensive Assessment

Metabolic Dysregulation and Its Multifaceted Impact on Cardiovascular Autonomic Control in Type 2 Diabetes Mellitus: Insights From Comprehensive Assessment

Source : https://www.cureus.com/articles/248895-metabolic-dysregulation-and-its-multifaceted-impact-on-cardiovascular-autonomic-control-in-type-2-diabetes-mellitus-insights-from-comprehensive-assessment

Background: Type 2 diabetes mellitus (T2DM) is associated with a spectrum of metabolic dysfunctions that significantly elevate the risk of cardiovascular disorders. Understanding the intricate relationship between metabolic control and...

Glycemic variability and dyslipidemia (elevated TG/LDL cholesterol, reduced HDL cholesterol) were associated with CV autonomic dysfunction.

Profile Image
  • Saved

Zerlasiran was well tolerated and produced sustained reductions in lipoprotein(a) concentrations.

Profile Image
  • Saved
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Source : https://pubmed.ncbi.nlm.nih.gov/38587249/

In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis...

Each dose of olezarsen also significantly reduced the levels of APOC3, apolipoprotein B, and non-HDL cholesterol, with no significant change in the LDL cholesterol level.

Profile Image
  • Saved

Dietary cholesterol consumption was not associated with incident diabetes and CVD in the overall sample and in subgroups stratified by genetic predisposition to cholesterol absorption and the diseases.

Profile Image